1. Home
  2. MPB vs DRUG Comparison

MPB vs DRUG Comparison

Compare MPB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$32.63

Market Cap

856.0M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$87.80

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
DRUG
Founded
1868
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
856.0M
707.1M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
MPB
DRUG
Price
$32.63
$87.80
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$37.00
$129.25
AVG Volume (30 Days)
107.3K
208.4K
Earning Date
04-21-2026
05-15-2026
Dividend Yield
2.66%
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
N/A
N/A
Revenue This Year
$30.95
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
$90.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$23.18
52 Week High
$35.22
$123.75

Technical Indicators

Market Signals
Indicator
MPB
DRUG
Relative Strength Index (RSI) 50.68 56.62
Support Level $30.66 $70.35
Resistance Level $34.88 $91.69
Average True Range (ATR) 0.77 4.92
MACD 0.10 0.72
Stochastic Oscillator 78.30 78.51

Price Performance

Historical Comparison
MPB
DRUG

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc is a financial holding company, providing various banking and financial products and services through its subsidiaries. These products and services mainly include consumer banking products, including secure checking and savings accounts, mobile banking, agricultural loans, construction financing, mortgages, home equity loans and lines of credit, credit cards, and more. Additionally, the Group offers trust services, insurance products, wealth management, and private banking services. The Group caters to individuals, partnerships, non-profit organizations, and corporations through its retail banking offices located throughout Pennsylvania, with a minor portion in New Jersey.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: